Diana Elizabeth Tullis


Associate Scientist, Li Ka Shing Knowledge Institute


As the Director of the Toronto Adult Cystic Fibrosis (CF) Clinic at St. Michael’s Hospital, Dr. Tullis is responsible for the care of 450 adults with CF. Dr. Tullis is a Professor of Medicine at the University of Toronto, the Respirology Division Head at St. Michael’s Hospital, and an Associate Scientist in the Li Ka Shing Knowledge Institute. She is the Cystic Fibrosis Canada Chair in Adult CF Research.

Dr. Tullis has published over 100 articles and book chapters and has lectured nationally and internationally on issues related to CF in adults. She has had 25 years of experience with CF clinical care. She was the Chair of the Clinic Subcommittee of the Medical/Scientific Advisory Board of Cystic Fibrosis Canada from 2005-2011 and in 2010 was a Coach for the Adult Quality Improvement Program run by the American Cystic Fibrosis Foundation.

Recent Publications

  1. Langawi, MA, Byrnes, C, Davies, JC, Hamouda, S, Kabra, M, Rached, SZ et al.. 'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020. J. Cyst. Fibros. 2020; :. doi: 10.1016/j.jcf.2020.02.021. PubMed PMID:32156627 .
  2. Middleton, PG, Mall, MA, Dřevínek, P, Lands, LC, McKone, EF, Polineni, D et al.. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N. Engl. J. Med. 2019;381 (19):1809-1819. doi: 10.1056/NEJMoa1908639. PubMed PMID:31697873 .
  3. Heijerman, HGM, McKone, EF, Downey, DG, Van Braeckel, E, Rowe, SM, Tullis, E et al.. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394 (10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. PubMed PMID:31679946 .
  4. Mejia, JF, Hirschi, KM, Tsai, KYF, Long, MG, Tullis, BC, Bitter, EEK et al.. Differential placental ceramide levels during gestational diabetes mellitus (GDM). Reprod. Biol. Endocrinol. 2019;17 (1):81. doi: 10.1186/s12958-019-0523-6. PubMed PMID:31647034 PubMed Central PMC6813062.
  5. Singh, AN, Oehler, J, Torrecilla, I, Kilgas, S, Li, S, Vaz, B et al.. The p97-Ataxin 3 complex regulates homeostasis of the DNA damage response E3 ubiquitin ligase RNF8. EMBO J. 2019;38 (21):e102361. doi: 10.15252/embj.2019102361. PubMed PMID:31613024 PubMed Central PMC6826192.
  6. Bell, SC, Mall, MA, Gutierrez, H, Macek, M, Madge, S, Davies, JC et al.. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8 (1):65-124. doi: 10.1016/S2213-2600(19)30337-6. PubMed PMID:31570318 .
  7. Clark, ST, Sinha, U, Zhang, Y, Wang, PW, Donaldson, SL, Coburn, B et al.. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams. Int. J. Antimicrob. Agents. 2019;53 (5):620-628. doi: 10.1016/j.ijantimicag.2019.01.009. PubMed PMID:30664925 .
  8. Diaz Caballero, J, Clark, ST, Wang, PW, Donaldson, SL, Coburn, B, Tullis, DE et al.. A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans. PLoS Pathog. 2018;14 (12):e1007453. doi: 10.1371/journal.ppat.1007453. PubMed PMID:30532201 PubMed Central PMC6300292.
  9. Davies, JC, Moskowitz, SM, Brown, C, Horsley, A, Mall, MA, McKone, EF et al.. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N. Engl. J. Med. 2018;379 (17):1599-1611. doi: 10.1056/NEJMoa1807119. PubMed PMID:30334693 PubMed Central PMC6277022.
  10. Keating, D, Marigowda, G, Burr, L, Daines, C, Mall, MA, McKone, EF et al.. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N. Engl. J. Med. 2018;379 (17):1612-1620. doi: 10.1056/NEJMoa1807120. PubMed PMID:30334692 PubMed Central PMC6289290.
Search PubMed

Affiliations & Other Activities

  • Head, Division of Respirology, St. Michael’s Hospital
  • The Cystic Fibrosis Canada Chair in Adult Cystic Fibrosis Research, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto